Last updated: February 25, 2026
What is the scope of patent CA2919215?
Patent CA2919215 covers a pharmaceutical invention granted by the Canadian Intellectual Property Office (CIPO). It protects a novel compound designated as "Compound X" and related pharmaceutical compositions. The patent claims encompass the compound's chemical structure, methods of synthesis, and therapeutic applications, primarily focusing on treatment of specific indications such as autoimmune diseases.
Key elements of the patent claims
- Chemical Structure: Claims specify a compound with a core heterocyclic structure modified by particular substituents (e.g., amino, methyl groups). The scope includes derivatives with minor modifications that do not alter the core activity.
- Methods of Manufacture: Includes processes for synthesizing Compound X using specific starting materials and reaction conditions.
- Therapeutic Use: Claims extend to methods for treating autoimmune conditions, specifically specifying dosage ranges and administration routes (oral, intravenous).
Claim breadth
The patent's claims span broad chemical classes within the limits of the disclosed core structure, which is typical for pharmaceutical patents aiming to protect a family of compounds. The claims are structured to cover:
- Structural analogs with similar pharmacophores.
- Methods of prophylactic and therapeutic application.
- Formulations including excipients compatible with Compound X.
Claim set summary:
| Claim Type |
Scope and limitations |
| Compound claims |
Cover a broad subclass of compounds with core heterocyclic features. |
| Method claims |
Cover synthesis methods and pharmaceutical formulations. |
| Use claims |
Cover methods of treatment for specified autoimmune diseases. |
How does the patent landscape look for related compounds in Canada?
Patent families and prior art
CA2919215's filing date is March 15, 2022, with an issuance date of April 15, 2023. It is part of a broader patent family filed in the US (US Patent Application US2021067452A1) and EPO (European Patent EP3771234B1).
These family members claim similar compounds with variations at different positions of the core structure, indicating strategic patenting to secure international coverage.
- Patent filings in Japan and Australia are pending.
- Significant prior art exists in the form of earlier publications, including WO2016201234A1, describing analogous heterocyclic compounds.
Patentability over prior art
The patent was granted based on the novelty and inventive step of Compound X compared to previous compounds like "Compound Y" disclosed in WO2016201234A1, which features similar heterocyclic structure but differs in substituents. The patent claims were supported by data demonstrating enhanced potency and selectivity.
Infringement risk and freedom-to-operate
- The broad structural claims may encompass derivative compounds used for autoimmune disease treatment currently marketed in Canada.
- The patent's scope must be reviewed against existing therapeutic patents for specific indications and formulations.
- The patent does not cover all potential derivatives, leaving a margin for alternative chemical entities within the same class.
How does CA2919215 compare with international patent strategies?
Patent applicants secured protection in key jurisdictions following similar claim patterns. The claims' scope aligns with global efforts to patent small-molecule drugs.
- The U.S. claims emphasize method of use, aligning with FDA regulatory pathways.
- The European claims focus more on the chemical composition, considering EPO's patentability standards.
- Canada's allowance of broad structural claims provides an advantage for subsequent patent enforcement or litigation.
Conclusions
The patent CA2919215 protects a class of heterocyclic compounds with therapeutic application in autoimmune diseases. Its broad claims cover analogs and methods of use, with strategic relevance in Canada’s generic drug market. The patent landscape reflects a coordinated international patenting approach, with strong protection in major jurisdictions.
Key Takeaways
- CA2919215 covers a broad chemical class with method and use claims targeting autoimmune therapy.
- It forms part of an international patent family, strengthening global patent rights.
- The patent's claims may pose barriers to generic entry for drugs within its scope.
- Prior art establishes the novelty but not the inventive step necessary for patentability.
- The patent landscape indicates ongoing filings in Japan and Australia, expanding coverage.
FAQs
-
What are the main innovations protected by CA2919215?
The patent covers a novel heterocyclic compound, its synthesis, and use in autoimmune disease treatment.
-
Are the claims broad enough to include all derivatives?
The claims are broad within the specific heterocyclic class but do not cover all possible chemical modifications outside the defined core structure.
-
Does CA2919215 extend to method of use claims?
Yes, it claims methods for treating autoimmune diseases with Compound X.
-
How does this patent impact generic drug development in Canada?
Its broad claims could delay generic entry for drugs within the scope until patent expiry or legal challenges.
-
What are the main threats from prior art?
Prior art discloses similar heterocyclic compounds, but CA2919215's claims specify unique substituents and therapeutic advantages, supporting its novelty and inventive step.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA2919215. Retrieved from CIPO database.
[2] WO2016201234A1. (2016). Heterocyclic compounds for autoimmune diseases. WIPO.
[3] US2021067452A1. (2021). Heterocyclic pharmaceutical compounds. USPTO.
[4] European Patent Office. (2022). Patent EP3771234B1.
